3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Dexamethasone
178
Bortezomib
100
Lenalidomide
90
daratumumab
47
Melphalan
46
Thalidomide
44
pomalidomide
43
Cyclophosphamide
38
Calcium Dobesilate
30
carfilzomib
29
Prednisone
19
Doxorubicin
16
elotuzumab
14
Filgrastim
14
isatuximab
12
ixazomib
11
Granulocyte Colony-Stimulating Factor
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
dexamethasone acetate
9
belantamab mafodotin
9
Zoledronic Acid
8
selinexor
7
Epoetin Alfa
7
fludarabine
6
Etoposide
6
dexamethasone 21-phosphate
5
auricularum
5
Mycophenolic Acid
5
Cisplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
birtamimab
×
Plasma cell
×
Clear all
NCT02312206
2023-11-14
VITAL
Prothena Biosciences Ltd.
Phase 3
Terminated
260 enrolled
11 charts